| HOME >> BIOLOGY >> TECHNOLOGY |
respectively.
(j) Consolidated equity compensation expense included in both reported and
adjusted results is $11.8 and $12.5 in 2007 and 2006, respectively,
aside from the 2006 charge discussed in note (e).
(k) Pro forma results combine the results of the company with the pre-
merger results of Fisher Scientific International Inc. Equity
compensation expense of $17.5 is included in the pro forma 2006
results.
Note: Consolidated net capital expenditures in Q4 2007 totaled $53.0.
Consolidated Statement of Income (a)
Twelve Months Ended
December December
31, % of 31, % of
(In millions except per share 2007 Revenues 2006 Revenues
amounts)
Revenues $9,746.4 $3,791.6
Costs and Operating Expenses
(e)(i)(j):
Cost of revenues 5,820.3 59.7% 2,210.2 58.3%
Selling, general and
administrative expenses 2,099.7 21.5% 952.7 25.1%
Amortization of acquisition-
related intangible assets 571.1 5.9% 170.8 4.5%
Research and development expenses 238.7 2.4% 170.2 4.5%
Restructuring and other costs, net
(d) 42.2 0.4% 45.7 1.2%
8,772.0 90.0% 3,549.6 93.6%
Operating Income 974.4 10.0% 242.0 6.4%
Interest Income 46.5 16.4
Interest Expense (f) (139.8) (51.9)
Other Income, Net (g) 0.2 2.9
Income from Continui
'/>"/>
| SOURCE Thermo Fisher Scientific Inc. Copyright©2008 PR Newswire. All rights reserved |